New Personalized mRNA Cancer Treatments Show Promise Against Melanoma and Other Cancers

Recent results from a large Phase 3 trial by Merck and Moderna offer cautious optimism in the fight against cancer, particularly aggressive skin cancer melanoma. The study tested a personalized mRNA treatment that sequences a patient’s tumor DNA to identify unique mutations, then creates a custom mRNA therapy to train the immune system to target cancer cells. Experts describe this as a significant breakthrough, though not a cure-all, marking another step forward in oncology alongside immunotherapy and targeted drugs.

Prof. Gal Markel of Davidoff Cancer Center at Beilinson Hospital emphasized the importance of this personalized approach, calling it an additional "building block" in cancer treatment. Prof. Raanan Berger from Sheba Medical Center noted that while this therapy helps prevent melanoma recurrence, it does not yet address metastatic or other advanced cancers. Unlike traditional vaccines, these treatments are given to patients post-diagnosis to stimulate immune recognition of tumor-specific neoantigens.

The technology leverages advances in genetic sequencing and mRNA production, accelerated by COVID-19 vaccine development. Moderna and Merck are expanding trials to other cancers including lung, bladder, kidney, and pancreatic cancers. Early-phase pancreatic cancer trials showed promising immune responses and improved survival rates among responders. Researchers are also exploring universal vaccines targeting common cancer mutations like KRAS.

Looking ahead, experts anticipate deeper integration of genetics, immunotherapy, and artificial intelligence to enhance treatment precision and speed. However, challenges remain in making these advanced therapies widely accessible due to high costs and healthcare budget constraints. Prof. Berger highlighted disparities in treatment availability and the need for policy decisions balancing innovation with affordability.

While these personalized mRNA therapies represent a major advance, the fight against cancer continues with ongoing research and development needed to broaden their impact and accessibility.